bluuebunny/crossref_metadata_2025_split huggingface dataset:
Evolution and role of mergers in the BCG–cluster alignment. A view from cosmological hydrosimulations
Authors: Ragone-Figueroa C , Granato G L , Borgani S , De Propris R , García Lambas D , Murante G , Rasia E , West M 
Published: May 2020

ABSTRACT
Contradictory results have been reported on the time evolution of the alignment between clusters and their brightest cluster galaxy (BCG). We study this topic by analysing cosmological hydrosimulations of 24 massive clusters with $M_{200}|_{z=0} \gtrsim 10^{15}\, \rm {\, M_{\odot }}$, plus 5 less massive with $1 \times 10^{14} \lesssim M_{200}|_{z=0} \lesssim 7 \times 10^{14}\, \rm {\, M_{\odot }}$, which have already proven to produce realistic BCG masses. We compute the BCG alignment with both the distribution of cluster galaxies and the dark matter (DM) halo. At redshift z = 0, the major axes of the simulated BCGs and their host cluster galaxy distributions are aligned on average within 20°. The BCG alignment with the DM halo is even tighter. The alignment persists up to z ≲ 2 with no evident evolution. This result continues, although with a weaker signal, when considering the projected alignment. The cluster alignment with the surrounding distribution of matter (3R200) is already in place at z ∼ 4 with a typical angle of 35°, before the BCG–cluster alignment develops. The BCG turns out to be also aligned with the same matter distribution, albeit always to a lesser extent. These results taken together might imply that the BCG–cluster alignment occurs in an outside–in fashion. Depending on their frequency and geometry, mergers can promote, destroy or weaken the alignments. Clusters that do not experience recent major mergers are typically more relaxed and aligned with their BCG. In turn, accretions closer to the cluster elongation axis tend to improve the alignment as opposed to accretions closer to the cluster minor axis.
Microsurgical Clipping of an Unruptured Basilar Apex Aneurysm: 2-Dimensional Operative Video
Authors: Hendricks Benjamin K , Spetzler Robert F 
Published: May 2020

Abstract
Aneurysms of the basilar artery apex are generally at an increased risk of rupture compared with aneurysms in other locations, and the risk of rupture increases with increasing aneurysm size. Therefore, these lesions necessitate treatment to decrease the risk of rupture. The location, size, and directionality of dome projection influence the difficulty of microsurgical treatment. The patient presented with an incidental basilar apex aneurysm identified on workup for headaches. The aneurysm projected superoposteriorly into the interpeduncular cistern. The surgical approach involved a wide exposure of the basilar apex complex and meticulous identification and preservation of P1 perforators during clip applications. It was imperative to visualize all perforators on both sides of the clip prior to application, given the severe morbidity associated with a perforator infarct. The patient tolerated the procedure well and remained neurologically intact after the operation. This video is an exemplary demonstration of basilar apex aneurysm clip application for an incidentally discovered aneurysm. The patient gave informed consent for surgery and video recording. Institutional review board approval was deemed unnecessary. Used with permission from Barrow Neurological Institute, Phoenix, Arizona.
Hunterian Ligation With Distal Revascularization for Management of a Previously Coiled Giant Internal Cerebral Artery Aneurysm: 2-Dimensional Operative Video
Authors: Hendricks Benjamin K , Spetzler Robert F 
Published: May 2020

Abstract
Unclippable giant aneurysms pose a significant microsurgical challenge. Options for management are highly dependent on the aneurysm characteristics and cerebrovascular anatomy. Hunterian (proximal) ligation with either high-flow or low-flow distal revascularization is an option for the treatment of aneurysms of the internal carotid artery (ICA). This patient had a multiply recurrent supraclinoid ICA aneurysm following endovascular treatment and progressive ipsilateral homonymous hemianopsia. In preparation for the clip occlusion of the proximal ICA, the patient underwent a balloon test occlusion of the ICA, which had a negative result, indicative of tolerance. A pterional craniotomy was used to perform a low-flow bypass, superficial temporal artery to M2, and clip occlusion of the proximal ICA. The patient tolerated the procedure well with some pressure-dependent contralateral symptoms, which resolved. The patient gave informed consent for surgery and video recording. Institutional review board approval was deemed unnecessary. Used with permission from Barrow Neurological Institute, Phoenix, Arizona.
Spatially resolved molecular gas properties of host galaxy of Type I superluminous supernova SN 2017egm
Authors: Hatsukade Bunyo , Morokuma-Matsui Kana , Hayashi Masao , Tominaga Nozomu , Tamura Yoichi , Niinuma Kotaro , Motogi Kazuhiro , Morokuma Tomoki , Matsuda Yuichi 
Published: May 2020

Abstract
We present the results of CO(1–0) observations of the host galaxy of a Type I superluminous supernova (SLSN-I), SN 2017egm, one of the closest SLSNe-I at z = 0.03063, by using the Atacama Large Millimeter/submillimeter Array. The molecular gas mass of the host galaxy is Mgas = (4.8 ± 0.3) × 109 M⊙, placing it on the sequence of normal star-forming galaxies in an Mgas–star-formation rate (SFR) plane. The molecular hydrogen column density at the location of SN 2017egm is higher than that of the Type II SN PTF10bgl, which is also located in the same host galaxy, and those of other Type II and Ia SNe located in different galaxies, suggesting that SLSNe-I have a preference for a dense molecular gas environment. On the other hand, the column density at the location of SN 2017egm is comparable to those of Type Ibc SNe. The surface densities of molecular gas and the SFR at the location of SN 2017egm are consistent with those of spatially resolved local star-forming galaxies and follow the Schmidt–Kennicutt relation. These facts suggest that SLSNe-I can occur in environments with the same star-formation mechanism as in normal star-forming galaxies.
Descriptive analysis of social determinant factors in urban communities affected by COVID-19
Authors: Harlem Gunness 
Published: May 2020

ABSTRACT

Objectives
To provide a descriptive analysis of communities severely impacted by COVID-19 to that of communities moderately affected by COVID-19, with an emphasis on the social determinant factors within them.

Methods
To compare the communities with extremely high COVID-19 rates to that of communities with moderate COVID-19 cases, we selected six community districts in Queens, New York using public data from New York City Health Department that provides the percentage of positive COVID-19 cases by zip codes from March 1st, 2020 to April 17th, 2020.

Results
The results of the study showed that COVID-19 cases were 30% greater in communities with extremely high cases than in communities with moderate cases. There were also the several outstanding social determinants commonalities that were found in communities with extremely high COVID-19 cases. These include severe overcrowding, lower educational status, less access to healthcare, and more chronic diseases.

Conclusion
This study adds to existing literature on vulnerable urban communities affected by COVID-19. Future studies should focus on the underlying factors in each social determinant discussed in this study to better understand its association with the spread of COVID-19.
O1.2. REDUCING THE DURATION OF UNTREATED PSYCHOSIS IN A U.S. CATCHMENT: THE MINDMAP CAMPAIGN
Authors: Srihari Vinod , Ferrara Maria , Kline Emily , Li Fangyong , Burke Shadie , Cahill John , Guloksuz Sinan , Woods Scott , Tek Cenk , Keshavan Matcheri 
Published: May 2020

Abstract

Background
The Specialized Treatment Early in Psychosis (STEP) program has delivered a specialty-team based first-episode service (FES) since 2006 in New Haven. In 2015, STEP launched a 4-year early detection (ED) campaign (Mindmap), adapted from the Scandinavian TIPS approach, to shorten Duration of Untreated Psychosis (DUP) in a 10-town catchment (popn. 400,000).

Methods
Mindmap’s social-ecological model targeted demand (delays in identifying illness and help-seeking) and supply (delays in referring to and providing FES) side constituents of DUP. Mindmap used mass and social media messaging, professional detailing, and rapid triage of referrals. DUP was measured as the time between the onset of psychosis and initiation of antipsychotic treatment (DUP1) and FES care (DUP2). A control FES (PREP, Boston) supported the quasi-experimental design. Quantile regression was used to interrogate the impact of the campaign across the full range of DUP. The campaign was launched in 2015, after a one-year baseline.

Results
The third quartile of DUP1 fell significantly at the intervention site in the pre- vs. post-campaign period (329 to 185 days, p=0.03). A time-series analysis revealed a cumulative effect of the campaign over time i.e. for each year of campaigning a 46-day reduction was achieved at STEP. DUP1 at the other quartiles and DUP2 across all quartiles showed a consistent trend of reduction over time at STEP, but this did not reach conventional statistical significance. At PREP both DUP1 & DUP2 remain unchanged, and comparable to baseline levels at STEP.

Discussion
Mindmap has shown promise in reducing delays to care and this is the first controlled demonstration of DUP reduction in a U.S. community setting. Additional data on help-seeking events and pathways to care and social media metrics will be presented as mediating variables. Mindmap was an early detection campaign hosted by an established FES and targeting a defined geographic catchment to recruit all incident cases. As such, this effort included a wide range of community and clinical stakeholders and modeled a population health based approach to the care of early psychosis. The lessons are relevant for burgeoning FES implementations across the world, and these will be elaborated based on the data and experience of implementing this study.
T44. 12-MONTH FOLLOW UP OF METABOLIC MEASURES FOLLOWING A RANDOMISED CONTROLLED TRIAL OF TREATMENT OF CLOZAPINE ASSOCIATED OBESITY AND DIABETES WITH EXENATIDE (CODEX)
Authors: Siskind Dan , Russell Anthony , Kisely Steve 
Published: May 2020

Abstract

Background
Clozapine is associated with high rates of obesity and type 2 diabetes (T2DM). Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, can counter clozapine-associated GLP-1 dysregulation. Our randomized, controlled (RCT), open-label, pilot trial of once-weekly extended-release subcutaneous exenatide or treatment as usual (TAU) for 24 weeks (n=28), found 6/14 people on exenatide achieved &gt;5% weight loss vs 1/14 receiving usual care (P = .029). Compared with TAU, participants on exenatide had greater mean weight loss body mass index (BMI) reduction, and reduced fasting glucose and glycated haemoglobin (HbA1c) levels.

Methods
We followed up CODEX trial participants at 12 months following the end of the trial. We collected information on weight, BMI, waist circumference, blood pressure, fasting glucose, HbA1c, and use of metformin. The primary outcome of interest was change in weight. Change in these parameters from trial baseline to 12 months post endpoint and trial endpoint to 12 months post endpoint was compared between those formerly in the exenatide and TAU arms.

Results
There were no significant differences between baseline and 12-months post endpoint for any of the variables. Data from endpoint to 12-month follow up point showed significantly greater increases among the former exenatide group compared to the former TAU group for weight, BMI, and proportion with &gt;5% weight gain. Stratifying the dataset by whether participants were on metformin six months after the end of the trial did not alter the overall results.

Discussion
There were significant increases in weight and BMI in the 12 months post endpoint for the former exenatide group, however there were no significant differences in weight and BMI between baseline and 12-month post endpoint. This is in keeping with other GLP-1RA studies. This information suggests the need for continued use of exenatide among people on clozapine who have achieved weight loss.
T53. NEUROPHYSIOLOGICAL AND BEHAVIORAL EFFECTS OF THE STIMULATION OF NICOTINIC RECEPTORS AND NON-INVASIVE BRAIN STIMULATION IN PATIENTS WITH SCHIZOPHRENIA: STUDY DESIGN AND METHODOLOGY OF A RANDOMIZED CONTROLLED TRIAL
Authors: Güler Duygu , Pross Benjamin , Nitsche Michael , Padberg Frank , Falkai Peter , Hasan Alkomiet 
Published: May 2020

Abstract

Background
Tobacco dependence is the most common substance use disorder in schizophrenia patients. Research suggests that prevalence rates for patients with schizophrenia are 40 to 80 percent. It is believed that these patients smoke to improve cognitive deficits. This assumption is supported by several neurophysiological and behavioral studies. The aim of the current study is to assess the physiological fundamentals and the behavioral effects of smoking in patients with schizophrenia.

Methods
The present randomized double-blind and controlled study is ongoing and focusses on enhancing cognitive functioning in schizophrenia patients. Nicotinic receptors of participating patients are stimulated by the substance varenicline. The resulting changes are assessed by non-invasive brain stimulation (NIBS) and cognitive performance tests. Additionally, anodal transcranial direct current stimulation (a-tDCS) is applied for inducing plasticity to examine the interaction between tobacco consumption and brain stimulation. The treatment consists of twice daily 1 mg of varenicline (or placebo) and 20-minute a-tDCS (or sham tDCS) over a period of five days. Sixty patients with schizophrenia will be recruited for this pilot study.

Results
This is a double-blind study. Therefore no results can be shown so far. To this date 18 patients have been recruited (female = 6). There haven’t been major side effects and patients are tolerating the interventions well.

Discussion
During the conference we will present the concept and design of the combined “varenicline x tDCS” trial for the treatment of cognitive deficits in schizophrenia.
T58. EFFECTIVENESS OF ORALLY ADMINISTERED CO-ENZYME Q10 FOR SCHIZOPHRENIA: COGNITIVE, FUNCTIONAL AND BIOCHEMICAL OUTCOMES FROM A DOUBLE BLIND, RANDOMISED, PLACEBO CONTROLLED TRIAL
Authors: Hargreaves April , Maguire Aine , Mooney Christina , Hargreaves Iain , Heaton Robert , Phillips Suzannah , Gill Michael 
Published: May 2020

Abstract

Background
Coenzyme Q10 (CoQ10) is an endogenous compound that is essential for energy production within the mitochondria and also functions as a potent anti-oxidant, inhibiting oxidative stress and damage. Often deficits in CoQ10 are associated with fatigue, and cognitive and psychological impairment. In light of its many functions, CoQ10 supplementation to minimise decline and improve symptoms has been investigated in multiple disorders including neurological and neuropsychiatric disorders, with results indicating positive effects on fatigue, cognitive impairment and affective difficulties for disorders such as bipolar disorder and chronic fatigue syndrome. There is also evidence of mitochondrial dysfunction in schizophrenia. In light of this evidence, the current study aimed to investigate the potential effect of CoQ10 supplementation on 1) cognitive function and 2) psychological and physical health in schizophrenia and schizoaffective disorder.

Methods
A double blind, randomised, placebo controlled study was conducted to assess the effects of CoQ10 supplementation (300mg/day) on cognitive, psychological and physical variables in 70 patients with schizophrenia and schizoaffective disorder. The effects of CoQ10 supplementation were compared to placebo at 3 and 6 months. Plasma CoQ10 was measured at all time points, along with measures of mitochondrial function (via plasma lactate concentration). Sensitivity analysis followed an intention to treat approach that used multiple imputations to account for missing values.

Results
Overall there was no effect of CoQ10 supplementation on cognitive outcome measures. This is despite observing an increase in plasma CoQ10 concentration in the CoQ10 group compared to the placebo. CoQ10 supplementation also had no effect on mitochondrial function, energy, psychological symptoms, quality of life, functional status, physical activity or blood pressure at either time point.

Discussion
There is considerable evidence that mitochondrial dysfunction is present in patients with schizophrenia and schizoaffective disorder, and this dysfunction is implicated in the manifestation of cognitive impairment and clinical symptoms. CoQ10 can be taken as a nutritional supplement with minimal side effects to target mitochondrial dysfunction via promoting ATP generation and increasing antioxidant capacity. However, we found no effect of CoQ10 supplementation on any variable under investigation. It is possible that CoQ10 might act as a protective agent against exacerbated oxidative stress in these patients, and future studies might be warranted to examine this possibility. However, the current data is conclusive that CoQ10 supplementation does not ameliorate existing deficits in schizophrenia. These findings are translatable to clinical and community settings.
M38. PATIENT-PERSPECTIVE: NEED FOR CARE AFTER A FIRST PSYCHOSIS
Authors: Heijden-Hobus Inge , van der Heijden-Hobus Inge , Rosema Bram-Sieben , Vorstman Jacob , Kas Martien , Begemann Marieke , Kikkert Martijn , Sommer Iris 
Published: May 2020

Abstract

Background
Only little is information is available about the needs and preferences regarding care and treatment of people who are going through a psychosis for the first time. A first psychotic episode is often an intense experience, which may not directly be recognized as a mental health problem. Given the unfamiliarity with the available options of care, it probably differs from subsequent psychoses. In order to design first psychosis programs to optimally meet patients preferences, we need to learn the care needs of these usually young people. Furthermore, peoples’ needs during the first psychosis, and the need for care after a psychotic episode have to be explored, in order to be able picking up life again after complete or incomplete remission.

Methods
Qualitative interviews were conducted with people (n = 20) who are in complete or partial remission after their first psychosis about their personal care needs. Interviews were conducted by an experience expert and a researcher together and lasted between 1 and 3 hours. Interviews were non-structured, but a basic set of 5 topics was used.

Results
Preliminary results of the interviews conducted so far (n = 14) show that people with a first psychosis have a great need for information about the symptoms they are suffering from. In addition, they believe that medication is an important ‘cornerstone’ to get rid of their symptoms. Furthermore, nearly all participants hope to be able to stop medication in the near future. Admission to a ward is in most cases experienced as frightening. One person indicated that the tranquility during admission was very welcome. At this stage, experience experts are not being reached out to yet, nor is there a clear need for social work in this stage of the disease. During and shortly after their first psychosis, the interviewees especially appreciate the support of family and close friends.

Discussion
Clear information about a first psychosis was mentioned as the first need. Family and close friends are most appreciated as “auxiliary troops”. Family support is therefore an important contributor in care for patients suffering from psychosis. Medication was appreciated as an important cornerstone, but only to induce remission, not as a mean for maintenance treatment. Admission was by most patients experienced as stressful. Additional research is recommended to further map what information this should be exactly, and how to bring it to the patient and his relatives.
M40. ECT VERSUS SHAM FOR CLOZAPINE RESISTANT SCHIZOPHRENIA: A SECONDARY ANALYSIS OF A PILOT STUDY BASED ON PANSS-30 FACTOR ANALYTIC DIMENSIONS AND THE PANSS-6
Authors: Luciana Melzer-Ribeiro Debora , Cristina Oliveira Solis Ana , Cistina Grilli Tissot Maria , Elkis Helio 
Published: May 2020

Abstract

Background
About 40% of patients with Treatment-Resistant Schizophrenia (TRS) do not respond to an adequate trial with clozapine and are termed Clozapine- Resistant Schizophrenia (CRS). A metanalysis showed that clozapine augmentation with ECT is efficacious for CRS, but no studies with Sham-ECT were reported (1). We published a pilot single-blinded study trial, which, to our knowledge, is the first to evaluate the efficacy of electroconvulsive therapy (ECT) in comparison with Sham–ECT in CRS (2) (NCT02049021) (PS). In this PS, patients with CRS received ECT (n=12) or SHAM-ECT (n=7) and after 12 sessions, but no differences were found between both groups as measured by the total PANSS and subscales at the endpoint. Factors, obtained by factor analytic studies (3), as well as individual items of shorter versions of the PANSS (4), are considered more valid predictors of TRS than subscales. The aim of the present study is a reanalysis of our PS based either PANSS factors obtained through factors analysis as well as on the individual items of the PANSS-30 and the PANSS-6.

Methods
We used individual participant data (IPD) at the symptom level, based on a statistical approach of a study already published (5). We used PANSS-30 items, traditional subscales, as well as factor scores (Positive, Negative and Cognitive) derived from our factor analysis of patients with TRS (4). Additionally, we analyzed also all the PANSS-6 items and the sum of scores (hallucinatory behavior –P3 and lack of spontaneity and flow of conversation- N6) which identify severe cases. STATA, Comprehensive Metanalysis, and R were used for calculations of effect sizes (fixed effects) and power

Results
We obtained significant differences between groups with high effect sizes (&gt;0.8) for three symptoms at endpoint: P3 (-0.993, 95% CI= -1.977 to -0.009, p= 0.048), N6 (-1.036, 95% CI= -2.025 to -0.047 p= 0.040), and Disorientation (G10) (-1.445, 95%CI=-2.48—0.40, p=0.006). The between-groups effect-sizes of other symptoms or factors showed no statistically significant differences

Discussion
The present reanalysis showed that patients with CRS do benefit from ECT treatment, with an improvement of their Hallucinatory Behavior or Lack of Spontaneity and Flow of Conversation, but suffer from some cognitive impairments (Disorientation). These findings are limited due to the small sample. We are conducting a trial with a much larger sample size to test the efficacy and tolerability of ECT vs Sham in CRS.